Adjunctive low-dose docosahexaenoic acid (DHA) for major depression: An open-label pilot trial

Autor: Deidre J Smith, Manjula O'Connor, Jerome Sarris, Nathan Dowling, Chee H. Ng
Rok vydání: 2017
Předmět:
Adult
Male
medicine.medical_specialty
Docosahexaenoic Acids
Placebo-controlled study
Medicine (miscellaneous)
Pilot Projects
Placebo
Severity of Illness Index
03 medical and health sciences
Depressive Disorder
Treatment-Resistant
0302 clinical medicine
Internal medicine
mental disorders
Severity of illness
medicine
Humans
Psychiatry
Depression (differential diagnoses)
Psychiatric Status Rating Scales
Depressive Disorder
Major
Nutrition and Dietetics
Depression
Mood Disorders
General Neuroscience
General Medicine
Middle Aged
medicine.disease
Combined Modality Therapy
Antidepressive Agents
030227 psychiatry
Diagnostic and Statistical Manual of Mental Disorders
Psychotherapy
Sleep Disorders
Intrinsic
Mood
Adjunctive treatment
Dietary Supplements
Clinical Global Impression
Major depressive disorder
Female
Psychology
030217 neurology & neurosurgery
Antipsychotic Agents
Zdroj: Nutritional neuroscience. 21(3)
ISSN: 1476-8305
Popis: Whilst the majority of evidence supports the adjunctive use of eicosapentaenoic acid (EPA) in improving mood, to date no study exists using low-dose docosahexaenoic acid (DHA) alone as an adjunctive treatment in patients with mild to moderate major depressive disorder (MDD).A naturalistic 8-week open-label pilot trial of low-dose DHA, (260 mg or 520 mg/day) in 28 patients with MDD who were non-responsive to medication or psychotherapy, with a Hamilton Depression Rating Scale (HAM-D) score of greater than 17, was conducted. Primary outcomes of depression, clinical severity, and daytime sleepiness were measured.After 8 weeks, 54% of patients had a ≥50% reduction on the HAM-D, and 45% were in remission (HAM-D ≤ 7). The eta-squared statistic (0.59) indicated a large effect size for the reduction of depression (equivalent to Cohen's d of 2.4). However confidence in this effect size is tempered due to the lack of a placebo. The mean score for the Clinical Global Impression Severity Scale was significantly improved by 1.28 points (P 0.05). Despite a significant reduction in the HAM-D score for middle insomnia (P = 0.02), the reduction in excessive daytime somnolence on the total Epworth Sleepiness Scale (ESS) did not reach significance. No significant adverse reactions to DHA were found.Within the major limits of this open-label pilot study, the results suggest that DHA may provide additional adjunctive benefits in patients with mild- to -moderate depression.
Databáze: OpenAIRE
Externí odkaz: